Back to Browse Journals » International Journal of Nephrology and Renovascular Disease » Volume 3

Fifteen years of losartan: what have we learned about losartan that can benefit chronic kidney disease patients?

Authors Elizabeth Ripley, Ari Hirsch

Published Date June 2010 Volume 2010:3 Pages 93—98

DOI http://dx.doi.org/10.2147/IJNRD.S7038

Published 28 June 2010

Elizabeth Ripley, Ari Hirsch

Division of Nephrology, Virginia Commonwealth University, Richmond, Virginia, USA

Abstract: Losartan, the first AT1 receptor blocker (ARB), was FDA approved 15 years ago.During those years, researchers and clinicians have developed a growing base of knowledge on the benefits of losartan, particularly for hypertension and renal disease. These benefits include decreasing proteinuria, slowing the progression of diabetic nephropathy, controlling hypertension, and decreasing stroke risk in patients with left ventricular hypertrophy. Although many of the benefits of losartan represent a class effect for ARBs, losartan has pharmacokinetic and pharmacodynamic characteristics and effects that are unique and are not a class effect. For example, a shorter duration of action is seen with this first ARB compared with other more recently approved ARBs. Losartan also has a uricosuric effect not seen in other ARBs and attenuates platelet aggregation, which is not seen or is seen to a lesser extent with the other ARBs. This review presents the physiological effects of losartan on the kidney and discusses relevant clinical outcomes.
Keywords: losartan, chronic kidney disease

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Drug development strategies for the treatment of obesity: how to ensure efficacy, safety, and sustainable weight loss

Barja-Fernandez S, Leis R, Casanueva FF, Seoane LM

Drug Design, Development and Therapy 2014, 8:2391-2400

Published Date: 1 December 2014

Insight into 144 patients with ocular vascular events during VEGF antagonist injections

Mansour AM, Shahin M, Kofoed PK, Parodi MB, Shami M, Schwartz SG

Clinical Ophthalmology 2012, 6:343-363

Published Date: 6 March 2012

Magnetic Fe3O4 nanoparticles and chemotherapy agents interact synergistically to induce apoptosis in lymphoma cells

Hongmei Jing, Jing Wang, Ping Yang, et al

International Journal of Nanomedicine 2010, 5:999-1004

Published Date: 19 November 2010

Correlation between penile cavernosal artery blood flow and retinal vascular findings in arteriogenic erectile dysfunction

Ahmed M Emarah, Shawky M El-Haggar, Ihab A Osman, et al

Clinical Ophthalmology 2010, 4:1047-1051

Published Date: 17 September 2010

Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis

Oghenowede Eyawo, Jean Nachega, Pierre Lefebvre, et al

Clinical Ophthalmology 2009, 3:447-456

Published Date: 31 July 2009

Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies

Arthur B Epstein, Peter T Van Hoven, Alan Kaufman, Warner W Carr

Clinical Ophthalmology 2009, 3:329-336

Published Date: 23 April 2009

Does wine prevent dementia?

Roger M Pinder

International Journal of Wine Research 2009, 1:41-52

Published Date: 4 February 2009